CAS 1312815-93-2

Formula: C26H29Cl2N3O3

InChI: InChI=1S/C26H29Cl2N3O3/c27-19-6-4-17(5-7-19)21-13-24-23(14-22(21)28)30-26(34-24)31-10-8-18(9-11-31)25(33)29-20-3-1-2-16(12-20)15-32/h4-7,13-14,16,18,20,32H,1-3,8-12,15H2,(H,29,33)/t16-,20-/m0/s1

InChI key: CPDNPVKDQXLYHO-JXFKEZNVSA-N

SMILES: C1C[C@@H](C[C@H](C1)NC(=O)C2CCN(CC2)C3=NC4=C(O3)C=C(C(=C4)Cl)C5=CC=C(C=C5)Cl)CO

PF-4693627

CAS: 1312815-93-2

PF-4693627

Formula: C₂₆H₂₉Cl₂N₃O₃

Purity: 99%

Molecular weight: 502.43

Ref: 54-OR1120720

PF-4693627

CAS: 1312815-93-2

Formula: C₂₆H₂₉Cl₂N₃O₃

Purity: 99%

Molecular weight: 502.4328

Ref: IN-DA00A1GM

PF-4693627

CAS: 1312815-93-2

PF-4693627 is an effective and selective microsomal prostaglandin E synthase-1 inhibitor (IC50=3 nM).

Formula: C₂₆H₂₉Cl₂N₃O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 502.43

Ref: TM-T16504

PF-4693627

CAS: 1312815-93-2

PF-4693627 is a potent, selective, and orally active prostaglandin E2 receptor agonist with pharmacological activity at the COX-2 enzyme. PF-4693627 has been shown to be effective in reducing inflammation and pain in animal models of inflammatory diseases, such as uveitis and arthritis. PF-4693627 is also being investigated for its potential use as an analgesic in humans. This drug has been shown to have a good safety profile in clinical studies.
PF-4693627 binds selectively to the prostaglandin E2 receptor subtype EP3 (COX-2) without significant binding to EP1 or EP2 receptors. This compound was developed by Pfizer Inc., which will be conducting Phase III clinical trials on this drug.

Formula: C₂₆H₂₉Cl₂N₃O₃

Purity: Min. 95%

Molecular weight: 502.4 g/mol

Ref: 3D-MCC81593